Literature DB >> 21293144

Basophil responsiveness and clinical picture of acetylsalicylic acid intolerance.

Peter Korosec1, Nusa Mavsar, Nissera Bajrovic, Mira Silar, Ales Mrhar, Mitja Kosnik.   

Abstract

BACKGROUND: Exposure to acetylsalicylic acid (ASA) may exacerbate respiratory or skin diseases or induce anaphylactoid reactions in apparently healthy individuals. We wanted to evaluate specific responsiveness of basophils to ASA in correlation with the clinical picture.
METHODS: We performed a prospective single-blind study of 59 subjects involved in clinical evaluation and/or ASA provocation testing. Whole blood basophils were stained with anti-CD63/CD123/HLA-DR mAbs after stimulation with 0.25 or 1 mg/ml ASA.
RESULTS: We found that 40 subjects were ASA tolerant and 19 were ASA intolerant. Both groups had comparable manifestations of asthma and/or rhinitis (13 in the tolerant and 9 in the intolerant group). Intolerant subjects showed significantly higher basophil responsiveness to ASA in comparison to tolerant subjects, which was concentration-dependent in both groups. The ratio between responses at 1 mg/ml of ASA and at baseline (activation index) was analyzed according to the clinical picture. We demonstrate that the activation index was higher only in the intolerant subjects with anaphylactoid reactions, but not in a subgroup of subjects with asthma/rhinitis. The ROC calculations show that the optimal threshold activation index was more than 2.18. The sensitivity was 80% and the specificity was 83% in the subgroup with anaphylactoid reactions. In the asthma/rhinitis subgroup, the sensitivity was 78% and the specificity was 50%.
CONCLUSIONS: Our study demonstrates that there is a significantly higher in vitro basophil response to ASA in intolerant as compared to tolerant subjects. ROC analyses suggest that this measurement might only have a diagnostic value in subjects without asthma and/or rhinitis.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293144     DOI: 10.1159/000319846

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

Review 1.  Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Authors:  Whitney Stevens; Kathleen Buchheit; Katherine N Cahill
Journal:  Curr Allergy Asthma Rep       Date:  2015-12       Impact factor: 4.806

Review 2.  BAT in the Diagnosis of Drug Allergy: a Novel Tool in Clinical Daily Practice?

Authors:  Lucila Campos; Violeta Régnier Galvão; Jorge Kalil; Mariana Castells; Pedro Giavina-Bianchi
Journal:  Curr Allergy Asthma Rep       Date:  2019-03-11       Impact factor: 4.806

Review 3.  Update on the performance and application of basophil activation tests.

Authors:  Emily C McGowan; Sarbjit Saini
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

Review 4.  Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis.

Authors:  Shao-Heng He; Hui-Yun Zhang; Xiao-Ning Zeng; Dong Chen; Ping-Chang Yang
Journal:  Acta Pharmacol Sin       Date:  2013-08-26       Impact factor: 6.150

Review 5.  In Vitro Diagnosis of Immediate Drug Hypersensitivity Anno 2017: Potentials and Limitations.

Authors:  I I Decuyper; E A Mangodt; A L Van Gasse; K Claesen; A Uyttebroek; M Faber; V Sabato; C H Bridts; C Mertens; M M Hagendorens; L S De Clerck; Didier G Ebo
Journal:  Drugs R D       Date:  2017-06

Review 6.  Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions.

Authors:  Yuttana Srinoulprasert; Ticha Rerkpattanapipat; Mongkhon Sompornrattanaphan; Chamard Wongsa; Duangjit Kanistanon
Journal:  Asia Pac Allergy       Date:  2020-10-29

Review 7.  Recent applications of basophil activation tests in the diagnosis of drug hypersensitivity.

Authors:  Woo-Jung Song; Yoon-Seok Chang
Journal:  Asia Pac Allergy       Date:  2013-10-31

Review 8.  Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations.

Authors:  Markus Steiner; Andrea Harrer; Martin Himly
Journal:  Front Pharmacol       Date:  2016-06-17       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.